PRone position in patients with spontaneous ventilation and acute hypoxemic respiratory failure - The PRONELIFE Randomized Controlled Trial

RESEARCH PROTOCOL

L. Morales-Quinteros1,2, M.J. Schultz3, A. Serpa-Neto3,9,10 M. Antonelli4, D.L. Grieco4, O. Roca6,8, N. Juffermans3, Ll. Blanch2,7,8, C. de Haro2,7, D. de Mendoza5, M. Camprubi-Rimblas2,8, A. Artigas2,7,8

Hospital Universitari Sant Pau, Barcelona, Spain
1Department of Intensive Care Medicine

Institut d'Investigació i Innovació Parc Taulí I3PT Universitat Autònoma de Barcelona Sabadell, Spain
2Translational Research Laboratory

Academic Medical Center, University of Amsterdam, The Netherlands
3Department of Intensive & Laboratory of Experimental Intensive Care and Anesthesiology

Catholic University of the Sacred Heart, "A. Gemelli" University Hospital, Rome, Italy
4Department of Anesthesiology and Intensive Care Medicine

Sagrat Cor University Hospital, Grupo Quironsalud, Barcelona, Spain
5Department of Intensive Care Medicine

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
6Department of Intensive Care Medicine & Vall d'Hebron Research Institute

Corporacion Sanitaria Universitaria Parc Tauli
7Department of Intensive Care Medicine

Instituto de Salud Carlos III, Madrid, Spain
8Centro de Investigación Biomédica en Red en Enfermedades Respiratorias

Hospital Israelita Albert Einstein, Sao Paulo, Brazil
9Department of Critical Care Medicine

Austin Hospital and University of Melbourne, Melbourne, VIC, Australia
10Department of Intensive Care Medicine
# TABLE OF CONTENTS

1. LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS ................................................. 4

2. SUMMARY ............................................................................................................................ 5

3. INTRODUCTION AND RATIONALE .................................................................................. 6
   3.1 Acute respiratory failure ................................................................................................. 6
   3.2 Complications of mechanical ventilation ..................................................................... 6
   3.3 Prone position in ARDS .................................................................................................. 6
   3.4 Prone position in spontaneously breathing patients ...................................................... 7

4. OBJECTIVES AND HYPOTHESIS .................................................................................... 8
   4.1 Objectives ....................................................................................................................... 8
   4.2 Hypothesis ...................................................................................................................... 8

5. STUDY DESIGN .................................................................................................................... 9

6. STUDY POPULATION .........................................................................................................10
   6.1 Population (base) ..........................................................................................................10
   6.2 Inclusion criteria ............................................................................................................10
   6.3 Exclusion criteria ...........................................................................................................10
   6.4 Sample size calculation ................................................................................................10

7. Study parameter/endpoints .................................................................................................12
   7.1 Main study parameters/endpoint ..................................................................................12
   7.2 Secondary study parameters/endpoints ........................................................................12
   7.3 Other optional substudy parameters ..........................................................................13

7.2 Study procedures ..............................................................................................................13
   7.2.1 Screening and Randomization ..................................................................................13
   7.2.2 Prone position ............................................................................................................14
   7.2.3 Standard management ..............................................................................................15
   7.2.4 Data to be collected ..................................................................................................17
   7.2.5 Blood samples (facultative) .....................................................................................20
   7.2.6 Assessment of regional ventilation (facultative) ........................................................20

8. STATISTICAL ANALYSIS ................................................................................................... 21
   8.1 Descriptive statistics .....................................................................................................21
   8.2 Analysis ..........................................................................................................................21
   8.3 Data Safety Management Board (DSMB) .....................................................................22
9. ETHICAL CONSIDERATIONS .................................................................................................................. 24
  9.1 Regulation statement ..................................................................................................................... 24
10. ADMINISTRATIVE ASPECTS AND PUBLICATION .......................................................................... 25
  10.1 Handling and storage of data and documents ............................................................................. 25
  10.2 Publication .................................................................................................................................... 25
11. REFERENCES ....................................................................................................................................... 26
12. APPENDICES ....................................................................................................................................... 29
## 1. LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS

<table>
<thead>
<tr>
<th>Abbreviation/Acronym</th>
<th>Full Wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>APACHE II</td>
<td>Acute physiology and chronic health disease classification system II</td>
</tr>
<tr>
<td>ARDS</td>
<td>Acute respiratory distress syndrome</td>
</tr>
<tr>
<td>BPS</td>
<td>Behavioral pain scale</td>
</tr>
<tr>
<td>BPsys</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>CCPOT</td>
<td>Critical care pain observation tool</td>
</tr>
<tr>
<td>CPAP</td>
<td>Continuous positive airway pressure</td>
</tr>
<tr>
<td>CRF</td>
<td>Case report form</td>
</tr>
<tr>
<td>EELI</td>
<td>End-expiratory lung impedance</td>
</tr>
<tr>
<td>FiO2</td>
<td>Fraction of inspired oxygen</td>
</tr>
<tr>
<td>HFNC</td>
<td>High-flow nasal cannula</td>
</tr>
<tr>
<td>HR</td>
<td>Heart rate</td>
</tr>
<tr>
<td>IMV</td>
<td>Invasive mechanical ventilation</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>NIV</td>
<td>Non-invasive ventilation</td>
</tr>
<tr>
<td>NPO</td>
<td>Nil per os</td>
</tr>
<tr>
<td>PaO2</td>
<td>Partial arterial oxygen pressure</td>
</tr>
<tr>
<td>PEEP</td>
<td>Positive end expiratory pressure</td>
</tr>
<tr>
<td>PP</td>
<td>Prone position</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>SAPS II</td>
<td>Simplified acute physiology score II</td>
</tr>
<tr>
<td>SOFA</td>
<td>Sequential Organ Failure Assessment</td>
</tr>
<tr>
<td>SP</td>
<td>Supine position</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected unexpected serious adverse reaction</td>
</tr>
<tr>
<td>VAS</td>
<td>Visual analogue scale</td>
</tr>
<tr>
<td>VFD</td>
<td>Ventilation-free days</td>
</tr>
</tbody>
</table>
2. SUMMARY

Rationale
It is uncertain whether awake prone positioning can prevent intubation for invasive ventilation in spontaneous breathing critically ill patients with acute hypoxemic respiratory failure. Awake prone positioning could benefit these patients for various reasons, including a reduction in direct harm to lung tissue, and prevention of tracheal intubation related complications.

Objectives
To compare standard care with awake prone positioning versus standard care without awake prone positioning in patients with acute hypoxemic respiratory failure from any cause

Hypothesis
Awake prone position in patients with acute hypoxemic respiratory failure is associated with a decreased need for intubation.

Study design
Investigator–initiated, international, multicenter, randomized clinical trial

Study population
Adult patients with acute hypoxemic respiratory failure (AHRF) from any cause.

Main study parameters/endpoints
The primary endpoint is a composite of tracheal intubation and all–cause mortality in the first 14 days after enrolment

Nature and extent of the burden and risks associated with participation, benefit, and group relatedness
A significant number of patients under awake proning will eventually require IMV. However, patients will be admitted to the ICU for close monitoring and do not delay intubation when indicated. If the hypothesis proves to be true, there is a potential decrease in intubation and IMV, reducing the risk of complications associated with it, facilitating the early onset of physiotherapy, and early ambulation. All these benefits would hasten recovery, improving short and long-term outcomes. Blood samples will be collected via an existing intravenous catheter or direct vein puncture, but always combined with blood sampling for routine care; the amount of additional blood samples can be considered minimal.
3. INTRODUCTION AND RATIONALE

3.1 Acute respiratory failure

Acute hypoxic respiratory failure represents one of the most common reasons for intensive care unit (ICU) admission\(^1\). Initial management of hypoxemic patients should involve immediate administration of simple supplemental oxygen via a nasal prong or a non-rebreather mask, or more complex forms of respiratory support like high-flow nasal oxygen (HFNO) oxygen or non-invasive ventilation (NIV), depending on severity of hypoxic respiratory failure and the underlying cause, but also patient characteristics and the availability of oxygen interfaces.

3.2 Complications of mechanical ventilation

Even though mechanical ventilation is a life-saving strategy in patients with respiratory failure, mechanical ventilation is associated with serious complications and intubation–related side effects. These complications may be related to the direct mechanical effects of the ventilator's intrathoracic pressures, alveolar and systemic inflammation, or neural stimulation\(^2\). Experimental\(^3-5\) and clinical\(^6\) studies show that MV has the potential to aggravate or even initiate lung injury (so-called ventilator-associated lung injury, VALI). Patients undergoing MV, sedation with or without paralysis are often required, especially for patients with shock or ARDS or those "fighting the ventilator."\(^7\) The use of sedative agents may unduly prolong MV's duration, precluding mobilization, promoting muscular deconditioning, and leading to detrimental short- and long-term outcomes\(^8,9\).

3.3 Prone position in ARDS

Prone positioning (PP) was first recognized for its ability to improve oxygenation and was historically used in the 1970s to improve gas exchange and salvage therapy for refractory hypoxemia\(^10\). A seminal multicenter trial and subsequent meta-analyses have made a compelling case that prone positioning in selected patients with severe acute respiratory distress syndrome (ARDS) early in their course improves survival\(^11\). This survival benefit is likely mediated by reduced VILI, as regional differences in lung aeration, compliance, and shear strain are minimized\(^12,13\).
3.4 Prone position in spontaneously breathing patients

In theory, nonintubated patients could also benefit from prone positioning\textsuperscript{14,15}, a strategy named 'awake prone positioning'\textsuperscript{16,17}. Some evidence for benefit of awake prone positioning comes from a handful of studies, mostly case reports and single–center observation case series\textsuperscript{15,18,19}.

Recently, two recent studies failed to show benefit of awake prone positioning in patients with acute respiratory failure\textsuperscript{20,21}. Of note, one of these studies had an observational design, and it remained uncertain whether the intervention was used as a routine or life–saving therapy\textsuperscript{21}. The other study was a randomized clinical trial that was underpowered for sample size estimation\textsuperscript{20}.

The findings thus far show that awake prone positioning can indeed improve oxygenation and also reduce dyspnea sensation. Besides that, awake prone positioning seems to be well–accepted and easy to perform, and to have relatively few side–effects\textsuperscript{22}. Therefore, awake prone positioning is an attractive intervention that could potentially be used as adjunctive therapy for patients with acute respiratory failure.
4. OBJECTIVES AND HYPOTHESIS

4.1 Objectives

The proposed randomized controlled trial aims at comparing the application of the prone position in spontaneously breathing patients with acute hypoxemic respiratory failure from any cause versus standard treatment on the rate of invasive mechanical ventilation or all-cause of mortality. The secondary endpoints will include time to tracheal intubation and effects of awake proning on the oxygenation parameters, dyspnea sensation, complications, and tolerance. Other endpoints are ventilation free-days at 28 days, duration of invasive ventilation, length of ICU and hospital stay, ICU and hospital mortality, and 28, 60, and 90-day mortality.

4.2 Hypothesis

We hypothesize that in adult patients with acute hypoxemic respiratory failure from any cause and spontaneous breathing, the prone position application decreases the intubation rate compared to the best standard of care.
5. STUDY DESIGN

Pragmatic, investigator-initiated, international, multicenter, parallel randomized clinical two-arm trial on acute hypoxemic respiratory failure patients with a respiratory rate of more than 25 breaths per minute, SpO₂ < 94% and FiO₂ of at least 40% or more by either Venturi facemask, HFNC or NIV/CPAP and, absence of decompensated respiratory acidosis.
6. STUDY POPULATION

6.1 Population (base)

We intend to recruit acute hypoxemic respiratory failure patients with a respiratory rate of more than 25 breaths per minute, SpO2 < 94% and FiO2 of at least 40% or more by either Venturi facemask, HFNC, or NIV/CPAP and, absence of decompensated respiratory acidosis during two years. Currently, we expect about 35 centers to participate in the trial. Demographic data and clinical characteristics on screened patients, regardless of enrolment criteria match, will be recorded (registry). We will randomize 650 patients admitted to the participating centers’ intensive care units and expect each participating center to randomize at least 25 patients who meet all inclusion criteria.

6.2 Inclusion criteria

- >18 years
- Acute respiratory failure from any cause
- Admitted to a participating ICU
- Written informed consent

6.3 Exclusion criteria

- Presence of any contraindication to prone position (APPENDIX i)
- The patient meets the criteria for intubation (see item 7.2.3)
- Participating in other interventional studies with the same primary outcome
- Receiving comfort care only
- Pregnancy

6.4 Sample size calculation

The sample size calculation was based on the primary outcome. The required sample size was calculated using data from two multicenter randomized controlled trials reporting intubation rates in patients with acute hypoxemic respiratory failure\textsuperscript{23,24}. The calculation indicated that 295 patients would be required per group, assuming a two-sided significance level of 0.05 and a power of 80%, to detect the expected difference in the rate of mechanical ventilation between the prone position group of 34% and the standard treatment group of
45% (risk ratio of 0.75). Assuming a dropout rate of 10%, a total of 650 patients (n= 325 per group) were planned to be included in the study.
7. METHODS

7.1 Study parameter/endpoints

7.1.1 Main study parameters/endpoint

- Composite endpoint comprising the rate of tracheal intubation or all-cause of mortality during the first fourteen days of enrolment

7.1.2 Secondary study parameters/endpoints

- Mortality at day 14
- Intubation among survivors at day 24
- Effects on oxygenation defined by the SpO₂
- Days under the oxygen support device
- Time to tracheal intubation
- Related complications. The following will be considered complications associated to the prone position:
  - Oxygen desaturations (SpO₂ <90%)
  - Episodes of hemodynamic instability (BPsys < 90mmHg or BPsys drop > 10mmHg if BPsys < 90 before the maneuver)
  - Need of orotracheal intubation
  - Cardiac arrest
  - Displacement of the non-invasive respiratory support device
  - Removal of central venous line, if documented
  - Displacement of an arterial line, if documented
  - Displacement of a urinary catheter, if documented

- Respiratory rate
- Dyspnea defined according to the Borg dyspnea scale (APPENDIX v)
- Duration of invasive mechanical ventilation in those patients who required intubation
- Ventilation-free days (VFD) at 28 days from ICU admission, defined as the number of days alive and free from IMV during the first 28 days from start of IMV
- ICU-free days and hospital-free days at day 90
- Mortality at day 28 and day 90
7.1.3 Other optional substudy parameters

- Systemic levels of biomarkers of lung injury
- Evaluation of regional ventilation distribution

7.2 Study procedures

Patients admitted to the participating centers' ICUs will be considered eligible if they fulfill the entry criteria. Eligible patients will be screened, their demographic criteria data recorded (registry: age, gender, type of oxygen support device), and those without exclusion criteria will be randomized. In total, 714 patients will be included.

Patient consent

According to local regulations, all patients or legal guardians must provide written informed consent before inclusion in the study. If patients cannot give informed consent due to the effects of acute illness, sedation, or hypoxemia, deferred consent will be obtained.

7.2.1 Screening and Randomization

Screening

The study will be carried out in the ICUs of the participating centers. Screening of patients in the Emergency Department and Hospitalization Ward can be done, if coordination with those Services has been demonstrated. This approach will ensure the early inclusion of patients and that the sample size is reached even earlier than expected and will improve the external validity of the study by increasing the spectrum of participating centers.

Randomization procedure

Randomization will be performed using a dedicated website and will be balanced per center and within 1 hour once the patient has been admitted to the ICU. An additional stratification for type of support received (Venturi, HFNC or NIV) will be done.

Randomization arms

Central randomization with the use of a permutated-block randomization list (block length 6) will be used. Participants will be allocated to the prone position or standard care on a 1:1 ratio.
7.2.2 Prone position

The best–fitting and most–tolerated oxygen interface will be used in the prone position—this could be different from patient to patient, and different from what is used in the supine position, and could differ between patients but also institutions (i.e., depending on the availability of masks with or without a reservoir bag and with or without the Venturi system, HFNO, CPAP or NIV).

Supine to Prone

The patient will be placed in the prone position for at least 2 hours, which may be prolonged if the patient is comfortable or interrupted if the patient presents any criteria for prone position discontinuation (APPENDIX ii).

During the maneuver, FiO₂ will be increased by 25% above the baseline and then gradually decreased to the baseline value within the first 10 minutes of prone positioning, targeting for a SpO₂ of 88-92%. The total time of the prone position will be recorded.

The maneuver will be performed by two operators and the attending physician, while in patients with impaired mobility, up to 5 operators will be required. Skin protections will be used to avoid pressure sores. Also, the application of cushions will enhance patient tolerance to the maneuver.

Arms can be at the side, in swimmer position, and can be moved to the patient's comfort. Vitals, SpO₂, and SpO₂/FiO₂ will be measured before and at the end of the prone position session.

Enteral or oral feeding will be interrupted 1 hour before prone positioning and re-established when the patient is in the semi-recumbent supine position.

Opiates, benzodiazepines, or alpha-2-adrenoceptor agonists can be used during the maneuvering at non-sedative doses to enable adaptation to the maneuver or treat anxiety symptoms related to respiratory failure.

If non-tolerance to the prone position, all clinical data will be collected, and the patients will be promptly rotated in the supine position. The reasons for prematurely unproning the patient will be accurately recorded. In case of sudden worsening of the oxygenation impairment or hemodynamics, 100% FiO₂ will be set, and the patient will be promptly positioned in the supine
semi-recumbent position.

Prone to Supine

After the prone position period, the patient will be rotated to the semi-recumbent supine position for at least 2 hours and a maximum of 4 hours. This 2-hour time frame will depend on nursing availability, need for hygiene, complementary explorations, or diet.

As described previously, for the procedure, FiO₂ will be increased up to 25% above the baseline and then gradually decreased to the baseline value within the following 10 minutes targeting a SpO₂ of 88-92%.

Vitals, SpO₂, and SpO₂/FiO₂ will be measured before and at the end of the supine position session.

Opiates, benzodiazepines, or alpha-2-adrenoceptor agonists can be used during maneuvering at non-sedative doses to enable adaptation to the maneuver or treat anxiety symptoms related to respiratory failure.

During the evening, the patient will be asked if the patient would prefer to remain supine or be rotated to prone according to the protocol.

If the patient remains hypoxemic, at clinician's criteria, the prone position could be continued more than 48 hours until respiratory failure improves.

7.2.3 Standard management

In all patients, whether receiving prone positioning or not, the best standard of care is provided, according to the standard care by the local teams.

When in a supine position, the patient will be placed in 30–45° semi–recumbent position but this can be changed for the comfort of the patient to supine, semi–sitting, sitting or a lateral decubitus position).

Vitals parameters, including SpO₂ and the SpO₂/FiO₂ are continuously monitored. The oxygenation target ranges for SpO₂ is 88% to 92%; this is 7 kPa to 8 kPa for PaO₂. For patients in whom the risk of potentially dangerous hypoxemia could be become unacceptable during the study (e.g., in patients who develop cardiac ischemia due to cardiac infarction or failed revascularization, or severe untreatable anemia such as with Jehovah's Witnesses), oxygenation target ranges can be higher, 94% to 96% for SpO₂ and 9 kPa to 11.5 kPa for PaO₂.⁴⁵–⁴⁷
Opiates and benzodiazepines are allowed at low dosages to improve comfort.

**INTUBATION CRITERIA**

The decision to continue with invasive mechanical ventilation is based on clinical judgment rather than isolated gasometrical criteria. Any of the following criteria should be considered for proceeding to endotracheal intubation:

- Respiratory or cardiac arrest;
- Respiratory pauses;
- Altered level of consciousness such as uncontrolled agitation not responding to medical treatment, or a drop in the Glasgow Coma Score;
- Evidence of exhaustion such as an unacceptable increase in use of accessory muscles or thoracoabdominal paradox;
- Inability to clear secretions from the airway in patients with abundant sputum production, or evidence of aspiration; or
- Hemodynamic instability as defined in Appendix iii

In addition, the presence of 2 of the following criteria within 1 hour of start non–invasive ventilatory support:

- Respiratory rate > 35 breaths/min, or increased respiratory rate from the baseline;
- Not improving or increased dyspnea;
- pH < 7.30 or less from its baseline, or PaCO$_2$ > 20% from the baseline value; or
- SpO$_2$ < 88%

**WEANING FROM THE NON–INVASIVE OXYGEN DELIVERY SYSTEM**

Weaning from the oxygen therapy delivery system will be done according to local protocols and preferences. Appendix iv provides guidance for oxygen requirements coupled with the reduction in gas flow rates of the HFNO.

**INVASIVE VENTILATION**

If patient continues with invasive ventilation, settings are chosen in line with the local guidelines for invasive ventilation. The use of lung–protective ventilation with a low tidal volume and low pressures is advocated. Also, sufficient levels of PEEP should be used, and prone positioning is to be applied if a patient meets develops severe hypoxemia, defined as PaO$_2$/FiO$_2$ < 150 mmHg at a minimum FiO$_2$ of 60% and 5 cm H$_2$O).

**FLUID REGIMENS**

We advise to use a restricted fluid strategy, i.e., targeting a neutral cumulative fluid balance
as soon as a patient can be weaned of vasopressors. Crystalloid infusions are preferred over colloid infusions.

SEDATION
In patients under invasive ventilation, the local guideline for sedation is to be followed, and preferably consists of combinations of use of analgo–sedation over hypno–sedation, use of bolus over continuous infusion of sedating agents, and the use of sedation scores (e.g., 3 times per day, and using a Richmond Agitation Sedation Scale\textsuperscript{28,29}. Also, the level of pain is to be determined, e.g. by using the Numeric Rating Scale, the Visual Analogue Scale (VAS), the Critical Care Pain Observation Tool (CCPOT) or Behavioral Pain Scale (BPS).

WEANING FROM INVASIVE VENTILATION
Weaning from invasive ventilation follows local protocols and preferences. In all patients, should be tested whether the patient accepts assist ventilation at least two times a day; this should also be tried when the patient shows respiratory muscle activity during assist ventilation. The attending physician decides when to extubate a patient, based on general extubation criteria (i.e., responsive and cooperative, adequate cough reflex, adequate oxygenation with FiO\textsubscript{2} ≤ 0.4, hemodynamically stable, no uncontrolled arrhythmia and a rectal temperature > 36° Celsius and after successfully passing a spontaneous breathing trial (SBT) with a T–piece or ventilation with minimal support (pressure support level < 10 cm H\textsubscript{2}O) and FiO\textsubscript{2} ≤ 0.4. In case SBTs are used, an SBT is judged as successful when the following criteria are met for at least 30 minutes, the attending physician takes the final decision for extubation:

- Respiratory rate < 35 breath/min;
- Peripheral oxygen saturation > 90%);
- Increase < 20% of heart rate and blood pressure; and
- No signs of anxiety and diaphoresis.

7.2.4 Data to be collected
The documentation of the data will adhere to the timetable in APPENDIX vi.

Pre-randomization variables
Pre-randomization variables will be collected:

- Gender and age; female + years
- Height and weight; kg + cm
• Date and time of hospital admission
• Source of admission to the ICU (emergency department, hospital ward, transfer from another ICU, transfer from a non-ICU ward of another hospital)
• Date and time of ICU admission
• Type of non-invasive respiratory support (HFNC, NIV, CPAP)
• COPD with inhalation therapy and/or steroids
• History of heart failure
• History of active cancer; if yes, specify the type of cancer
• History of diabetes mellitus; oral medication or insulin therapy
• History of hypertension
• History of chronic kidney disease
• History of cirrhosis
• Use of angiotensin-converting enzyme inhibitor
• Use of angiotensin II receptor blocker
• Use of calcium channels blocker
• Use of beta-blocker
• Use of diuretics
• Heparin/low molecular weight heparin
• Use of Remdesivir
• Use of Tocilizumab
• Actual organ function evaluation
  ▪ Respiratory rate
  ▪ $\text{SpO}_2; \%$
  ▪ $\text{SpO}_2/\text{FiO}_2$
  ▪ ROX index; $\text{SpO}_2/\text{FiO}_2; \text{RR}$
  ▪ Dyspnea defined according to Borg dyspnea scale
  ▪ Chest X-ray
  ▪ Non-invasive mean arterial pressure; mmHg
  ▪ Heart rate; BPM
  ▪ Body temperature; °C
  ▪ BUN, Creatinine, AST, ALT, Bilirubin, Hemoglobin, Platelets, PTT, WBC count
Post-randomization variables

One hour before each position change (supine and prone), the following variables will be collected for the duration of the protocol, which will be for 48 hours (APPENDIX vi):

- Organ function evaluation:
  - Respiratory rate
  - \( \text{SpO}_2 \); %
  - \( \text{SpO}_2 / \text{FiO}_2 \)
  - ROX index; \( \text{SpO}_2 / \text{FiO}_2 \); RR
  - Dyspnea defined according to the Borg dyspnea scale (APPENDIX v)
  - Non-invasive mean arterial pressure; mmHg
  - Heart rate; BPM

- Non-invasive support device parameters:
  - HFNC: flow; liters/min. \( \text{FiO}_2 \); %
  - CPAP: PEEP; cmH\textsubscript{2}O. Flow; liters/min; Tidal volume; ml. \( \text{FiO}_2 \); %
  - NIV: PEEP; cmH\textsubscript{2}O. Pressure support over PEEP; cmH\textsubscript{2}O. Flow; liters/min. Tidal volume; ml. \( \text{FiO}_2 \); %

- Complications possibly related to prone position:
  - New hypotension (BP\text{sys} < 90mmHg or BP\text{sys} drop > 10mmHg, if BP\text{sys} < 90 before the maneuver)
  - New bradycardia (HR <50bpm or HR drop > 20%, if HR < 50 before the maneuver)
  - New hypoxemia (\( \text{SpO}_2 \) ≤ 90% or \( \text{SpO}_2 \) drop > 5%, if \( \text{SpO}_2 \) < 90% before the maneuver)
  - Ulcers
  - Displacements of any of the following: respiratory support device, peripheral or venous central line, oro or nasogastric tube, urinary catheter

Post-protocol variables

The patients will be assessed daily between the third and the fourteenth day after the protocol.
and the last day before discharge from the ICU and the hospital. Discharge from critical care is defined as the first discharge to a medical or surgical ward in the hospital or another hospital; a transfer between ICUs is not considered a discharge from critical care. Hospital discharge is the first date that the patient is discharged to home/community; a transfer between hospitals is not considered as a hospital discharge. Clinical data and the presence of complications will be registered and the date of the development of any complication documented (see APPENDIX vii).

The following variables will be collected:

- Continuation of prone position
- Continuation and time spent under the non-invasive respiratory support device
- Day and time of unassisted breathing; i.e., no ventilatory support and use of conventional supplemental oxygen or room air
- Chest X-ray
- Need for invasive mechanical ventilation
- Any need for anti-arrhythmic and vasoactive medication; if yes: specify
- Date of ICU discharge
- Date of hospital discharge

### 7.2.5 Blood samples (facultative)

At randomization and the end of the protocol (48 hours) in both groups (supine and prone), and for those centers that have the storage capacity, blood samples (2 x 5 ml in EDTA, citrate, and heparin) will be collected and stored at -80°C for measurement of markers of lung injury (angiopoietin-2, surfactant proteins D, RAGE). Blood samples will be sent and processed at a central laboratory.

### 7.2.6 Assessment of regional ventilation (facultative)

Before (in supine) and at the end of the first and the last prone position, for those centers with electrical impedance tomography, we plan to investigate the effects of global and regional end-expiratory lung impedance variation (ΔEELI).
8. STATISTICAL ANALYSIS

8.1 Descriptive statistics

Patient characteristics will be compared and described by appropriate statistics.

8.2 Analysis

The goal of the primary outcome is to quantify the effect of prone position versus the standard treatment upon the need for invasive mechanical ventilation during the first fourteen days after randomization.

For the primary efficacy analysis rates of the composite of death and intubation will be compared between the two intervention groups, and the odds ratio relative risks with corresponding 95% confidence levels interval will be calculated using logistic regression analysis.

With regard to the remaining parameters: Normally distributed variables will be expressed by their mean and standard deviation; non-normally distributed variables will be expressed by their medians and interquartile ranges. Categorical variables will be expressed as n (%). Student's t-test will be used to test groups of continuous normally distributed variables. Conversely, if continuous data is non-normally distributed, the Mann-Whitney-U test will be used. Categorical variables will be compared with the Chi-square test, Fisher's exact tests, or, where appropriate, as relative risks. Time-to-event data will be analyzed using a Cox proportional hazard model adjusted for possible imbalances of patients' baseline characteristics.

COVID-19 status of patients will be taken into account and analyzed in the study to find any differences in the primary and secondary outcomes between COVID-19 and non-COVID-19 patients.

A stratified analysis will be done by the device used (HFNC, BIPAP, CPAP, and their interfaces).

The statistical analysis will be based on the intention–to–treat principle. Besides, we will perform a per-protocol analysis to check for the robustness of the results. The intention–to–treat analysis includes all patients as randomized regardless of whether they received the randomized treatment or other protocol deviations. Per–protocol group analysis only
considers those patients who completed the treatment according to the originally allocated protocol.

Data analyses will follow an a priori documented statistical analysis plan, which will be finalized before the end of data collection. By definition, only the analysis of the primary outcome is confirmatory; all other analyses are exploratory. The analysis will be undertaken blinded by a statistical expert. Statistical significance is considered to be at a p-value of 0.05, where 95% confidence levels will express appropriate statistical uncertainty.

The analysis will be performed with R statistics (R v.4.0.2).

8.3 Data Safety Management Board (DSMB)

A DSMB will be installed to monitor safety and the overall conduct of the trial. The DSMB will compose of 3 individuals who will be invited, one of which will be the chairperson.

The DSMB will first convene after the first 100 patients, approximately 6 months after the first patient is enrolled.

- Subsequently, the DSMB will attend videoconferences every six months
- All adverse events will be reported to the DSMB for review. All serious events will be reported within 24 hours after being received by the coordinating center. Non-serious events will be reported within one week of reception by the coordinating center (APPENDIX vi).
- Adverse events possibly occurring during this study include but are not limited to unexpected death or cardiac arrest in either the control or treatment group (APPENDIX vii).
- The DSMB will monitor the overall status of the trial: number of patients enrolled overall and per each center, adherence to protocol overall and per center and results of the interim analysis.
- The DSMB include any of the following individuals:
  - Prof. Claude Guerin. Réanimation Médicale, Hôpital de la Croix-Rousse, Hospices Civils de Lyon; Université de Lyon; and Creatis INSERM 1044, Lyon, France, (chair)
  - Prof. Arthur Slutsky. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada; Keenan Research Centre for Biomedical
Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.

- Dr. Tàì Pham. Université Paris-Saclay, AP-HP, Service de Médecine Intensive-Réanimation, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
9. ETHICAL CONSIDERATIONS

9.1 Regulation statement

This study, and any subsequent amendments to it, conforms/will conform to the World Medical Association Declaration of Helsinki as revised in October 2013 (64th General Assembly of the World Medical Association, Fortaleza, Brazil).
10. ADMINISTRATIVE ASPECTS AND PUBLICATION

10.1 Handling and storage of data and documents

All enrolled patients will receive a random patient identification code. The codebook will be stored digitally, encrypted with a double password, and hard copy under lock and key. All data will be stored for the study's length and afterward as required by local law or for further publication. All handling of personal data will comply with local law.

10.2 Publication

At the appropriate time, and by mutual consent in consultation with the Steering Committee, it is planned that the results of the clinical study will be published in a scientific journal and presented at national and international conferences. Publication of the complete clinical research should generally be the preferred option. The "Uniform requirements for manuscripts submitted to biomedical journals International Committee of Medical Journal Editors" will be applied.

All publications will comply with data protection requirements covering patient data and data relating to the participating clinicians. Any publication or presentation of this clinical study results requires prior notification and submission to the Steering Committee for purposes of comment and approval.
11. REFERENCES


12. APPENDICES

APPENDIX i. CONTRAINDICATIONS FOR PRONE POSITION

- Suspected increased intracranial pressure (e.g. severe brain injury)
- Hemoptysis
- Vomiting
- Recent abdominal wound (less than 15 days)
- Tracheal surgery or sternotomy during the previous 15 days
- Facial trauma or facial surgery during the previous 15 days
- Deep venous thrombosis treated for less than 2 days
- Cardiac pacemaker inserted in the last 2 days
- Unstable spine, femur, or pelvic fractures
- Hemodynamic instability (defined by a systolic blood pressure below 90 mmHg, a mean blood pressure below 65 mmHg or requirement for vasopressor)
- Pregnant women
- Presence of chest tube
APPENDIX ii. PRONE POSITION DISCONTINUATION (ANY OF THE FOLLOWING)

- Occurrence of contraindications (see APPENDIX i)
- Worsening of dyspnea according to the Borg scale after 15 minutes
- Drop in SpO2 <90% after 15 minutes
- Nausea/vomiting
- BPs < 90mmHg or BPs drop > 10mmHg, if BPs < 90 before the maneuver

APPENDIX iii. HEMODYNAMIC INSTABILITY DEFINITION

Defined as any of the following not responding to fluid resuscitation and unrelated to sedatives (if given):

- Systolic arterial pressure < 90 mmHg, or
- Mean arterial pressure < 65 mmHg, or
- Increased needs of vasopressor agents, or
- ECG evidence of ischemia or significant uncontrolled ventricular arrhythmia

APPENDIX iv. HIGH FLOW NASAL CANNULA SCHEME FOR OXYGEN REQUIREMENTS COUPLED WITH GAS FLOW RATES*

<table>
<thead>
<tr>
<th>FiO2</th>
<th>21-30%</th>
<th>30-40%</th>
<th>40-60%</th>
<th>60-100%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flow</td>
<td>30 L/min</td>
<td>30-40 L/min</td>
<td>40-50 L/min</td>
<td>50-70 L/min</td>
</tr>
</tbody>
</table>

* In case the patient is using NIV, sessions could be interrupted when the respiratory rate is < 25 breaths/min and the FiO2 <40% (for a SpO2 88%)
## APPENDIX v. BORG DYSPNEA SCALE

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Nothing at all</td>
</tr>
<tr>
<td>0.5</td>
<td>Very, very slight (just noticeable)</td>
</tr>
<tr>
<td>1</td>
<td>Very slight</td>
</tr>
<tr>
<td>2</td>
<td>Slight breathlessness</td>
</tr>
<tr>
<td>3</td>
<td>Moderate</td>
</tr>
<tr>
<td>4</td>
<td>Somewhat severe</td>
</tr>
<tr>
<td>5</td>
<td>Severe breathlessness</td>
</tr>
<tr>
<td>6</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Very severe breathlessness</td>
</tr>
<tr>
<td>8</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Very, very severe (almost maximal)</td>
</tr>
<tr>
<td>10</td>
<td>Maximal</td>
</tr>
</tbody>
</table>
# APPENDIX vi. TIMETABLE

<table>
<thead>
<tr>
<th></th>
<th>Before intervention</th>
<th>During intervention</th>
<th>End of intervention</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Day 6</th>
<th>Day 7</th>
<th>Day 14</th>
<th>Day of ICU discharge</th>
<th>Day of hospital discharge</th>
<th>Day 26</th>
<th>Day 90</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All patients eligible for the study</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening and Randomization</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daily screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic data (registry)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/Exclusion criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Randomized patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Before starting protocol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic data</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of previous disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SpO₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest X-ray</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Routine laboratory tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>During Protocol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory variables</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemodynamic variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regional ventilation variables (facultative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>End of Protocol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol dropout?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events (possibly related to prone position)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuation of prone position after the protocol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuation of ventilatory support</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sampling (special markers, facultative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Follow Up</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actual recovery status (ICU stay, ventilatory support)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SpO₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest X-ray (facultative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Routine laboratory tests (facultative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events (see APPENDIX vi)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of ICU discharge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of hospital discharge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alive on day 28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Alive on day 90</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Hospital-free days on day 90</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>
APPENDIX vii. ADVERSE EVENTS

1. Definitions
An adverse event (AE) is generally defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding) syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline, appears to worsen. Adverse events are to be recorded regardless of their relationship to the study intervention. With respect to intensity, adverse events are classified as follows:

- Mild some awareness of symptoms, but easily tolerated;
- Moderate symptoms causing enough discomfort to interfere with usual activity;
- Severe incapacitating event causing inability to work or to perform usual activity.

A Serious Adverse Event (SAE) is defined as any experience that suggests a significant hazard or side effect with respect to participants participating in a clinical study. This includes any experience which:

- is fatal or life threatening,
- is permanently disabling, i.e. incapacitating or interfering with the ability to resume normal life patterns,
- requires hospitalization or prolongation of hospitalization,
- requires other medically important circumstance (requires medical treatment to avoid one of the above mentioned conditions).

A special form of the SAE is the Suspected Unexpected Serious Adverse Reaction (SUSAR).

Adverse events possibly occurring during this study include but are not limited to unexpected death or cardiac arrest in either the control or treatment group.

2. Documentation of AEs and SAEs
All adverse events that occur between start of randomized intervention and 90-days follow up have to be immediately documented in the participant's electronic CRF. AEs are classified as either serious or non-serious. Details about the clinical symptoms, clinical course and if medical treated, about therapies used should be provided as well as information about relationship to
study intervention, overall intensity and outcome of the adverse event.

3. Reporting of Adverse Events

Reporting responsibilities of the local coordinator
Any AE occurring after start of randomized study intervention will be reported. The participant will be followed until remission of the symptoms. When reporting an AE/SAE, a clinical narrative on each AE/SAE should be added, which gives the clinical context of the event and allows the DSMB to carefully review the AE/SAEs.

AEs are reported via electronic CRF within one week of reception by the coordinating center. SAEs as well as all related or possibly related events and all unexpected events are reported via electronic CRF within 24 hours after being received by the coordinating center. In case of a SUSAR (suspected unexpected serious adverse reaction) as well as death of study patients the SAE manager has to be informed additionally by email.

Management of AE/SAE
The SAE manager collects and judges the reports within predefined time frames. All related or possibly related events and all unexpected events are forwarded to the DSMB for further review. The DMB members assess forwarded events and review all SAE and AE from all centers every six months or sooner if requested by them. If the DSMB rates an event related to the study therapy, the DSMB should inform the principal investigator.

In case of a SUSAR (suspected unexpected serious adverse reaction) and death of study patients, the ethics committee of the Institut d'Investigació i Innovació Parc Taulí (I3PT) will be informed within seven days. Additionally, a summary of all SAE will be provided twice per year.